Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Trujillo

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical and Translational Science|September 29, 2023
Evaluation of an online research best practices training for community health workers and promotorasSusan L Murphy, Gina M Jay, Elias M Samuels, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitorJohn I Trujillo, James R Kiefer, Wei Huang, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse AgonistsMark E Schnute, John I Trujillo, Katherine L Lee, et al.
Journal of Medicinal Chemistry|November 14, 2018
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent InhibitorsAgustin Casimiro-Garcia, John I Trujillo, Felix Vajdos, et al.
Journal of Medicinal Chemistry|February 17, 2025
Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 AntagonistsBrian S Gerstenberger, Ray Unwalla, Kathleen A Farley, et al.
Bioorganic & Medicinal Chemistry|April 8, 2020
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Journal of Medicinal Chemistry|February 1, 2017
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.
Nature Communications|May 16, 2025
Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.
ACS Chemical Biology|October 30, 2016
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective InhibitionJean-Baptiste Telliez, Martin E Dowty, Lu Wang, et al.
Nature Communications|August 31, 2024
Structural basis for CCR6 modulation by allosteric antagonistsDavid Jonathan Wasilko, Brian S Gerstenberger, Kathleen A Farley, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical and Translational Science|September 29, 2023
Evaluation of an online research best practices training for community health workers and promotorasSusan L Murphy, Gina M Jay, Elias M Samuels, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitorJohn I Trujillo, James R Kiefer, Wei Huang, et al.
ACS Medicinal Chemistry Letters|February 16, 2023
Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse AgonistsMark E Schnute, John I Trujillo, Katherine L Lee, et al.
Journal of Medicinal Chemistry|November 14, 2018
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent InhibitorsAgustin Casimiro-Garcia, John I Trujillo, Felix Vajdos, et al.
Journal of Medicinal Chemistry|February 17, 2025
Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 AntagonistsBrian S Gerstenberger, Ray Unwalla, Kathleen A Farley, et al.
Bioorganic & Medicinal Chemistry|April 8, 2020
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Journal of Medicinal Chemistry|February 1, 2017
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.
Nature Communications|May 16, 2025
Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding siteLeslie A Dakin, Li Xing, Justin Hall, et al.
ACS Chemical Biology|October 30, 2016
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective InhibitionJean-Baptiste Telliez, Martin E Dowty, Lu Wang, et al.
Nature Communications|August 31, 2024
Structural basis for CCR6 modulation by allosteric antagonistsDavid Jonathan Wasilko, Brian S Gerstenberger, Kathleen A Farley, et al.
Pageof 6